Compare SER & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SER | MURA |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 36.0M |
| IPO Year | 2018 | N/A |
| Metric | SER | MURA |
|---|---|---|
| Price | $3.10 | $2.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $13.00 | $6.00 |
| AVG Volume (30 Days) | 15.1K | ★ 224.8K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,000.00 | N/A |
| Revenue This Year | $134.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.12 | $0.95 |
| 52 Week High | $7.92 | $4.74 |
| Indicator | SER | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 29.42 | 40.39 |
| Support Level | $3.15 | $2.06 |
| Resistance Level | $4.26 | $2.10 |
| Average True Range (ATR) | 0.23 | 0.01 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 0.00 | 25.00 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.